Research
Read how they describe their research on their University of Toronto profile.
Latest papers
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.
Acta dermato-venereologica · 2026
SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement.
The British journal of dermatology · 2026
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials.
Rheumatology and therapy · 2025
16 publications.
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.
Thaçi D, Puig L, Motegi SI, Papp K, Stein Gold L, Kircik L, Sofen H, Fernández-Peñas P, Herranz P, Vestergaard C, Huang YH, Dossenbach M, Elmaraghy H, Gallo G, Rueda MJ, Casillas M, Yang C, Agell H, Falqués M, Nosbaum A
SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement.
Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J, Park-Wyllie L, Gao LL, Gordon KB, Merola JF, Lebwohl MG, Strober B
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials.
Östör A, Van den Bosch F, Papp K, Keiserman M, Blanco R, Crowley A, White D, Biljan A, Madihlaba T, Carter K, Liu F, Soliman AM, Ashley D, Chen M, Glotfelty L, Kivitz A
Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.
Blauvelt A, Papp K, Trivedi M, Barragan C, Chow V, Mytych DT, Yamauchi P, Crowley J, Franklin J
A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis.
Papp K, Balser S, Nopora K, Rewerski P, Freudensprung B, Trieb M
Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.
Tiraboschi G, Papp K, Bieber T, Weidinger S, Beck L, Lee CH, O'Malley JT, Yen K, Bernigaud C, Fabre D, Hurbin F
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
Miller M, Li S, Rich P, Kannan A, DeKlotz C, Bissonnette R, Pinter A, Ferris LK, Gerdes S, Vender R
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study
Papp K, Prajapati VH, Maari C, Legault M, Barakat M, Vender R
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey.
Lee EY, Turchin I, Chan AW, Beecker J, Bissonnette R, Catherall H, Cresswell-Melville A, Gooderham M, Hawkins N, Hong HC, Levell NJ, Lapointe McKenzie JA, Manion R, Papp K, Drucker AM
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS
Frequent collaborators
- An-Wen Chan and Aaron Drucker: 21 shared papers
- Ronald Vender and Kim Papp: 2 shared papers
- An-Wen Chan and Kim Papp: 1 shared paper
- Aaron Drucker and Kim Papp: 1 shared paper
- Department of Medicine
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.